Blood Cancer Screen
Hematological VitroScreen
Overview
Industry-leading Hematologic Model Screening
Largest primary hematological repository of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM) models
Well-characterized models featuring patient responses, clinical annotation, NGS data (WES and RNASeq), deep phenotyping using flow cytometry, proteomics, and phospho-proteomics datasets available in Lumin
Insights
Data-Driven Insights to Accelerate Your Hematologic Program
Our standard endpoint is a cell viability assessment by CellTiter-Glo®, and additional optional endpoints are available during each VitroScreen enrollment period to maximize the insight our partners can derive from each experiment.
Testimonials
"The Hematological VitroScreen from Champions Oncology has significantly enhanced our ability to evaluate drug efficacy and safety. The platform’s comprehensive data and high sensitivity have provided us with crucial insights into hematologic malignancies and drug interactions."
Senior Scientist, Pharmaceutical Company
"Champions Oncology’s Hematological VitroScreen has become a critical tool in our research arsenal. The platform’s high throughput and precise results have significantly improved our ability to screen and analyze potential therapies for blood cancers."
CSO, Biotech Company
"The Hematological VitroScreen from Champions Oncology has significantly enhanced our ability to evaluate drug efficacy and safety. The platform’s comprehensive data and high sensitivity have provided us with crucial insights into hematologic malignancies and drug interactions."
Senior Scientist, Pharmaceutical Company
Resources
Explore our resources
Autologous AML Platform
The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology (IO) drugs in only 4 days using primary patient models.
Get started